Skip to main content
. 2021 Sep 28;12(20):2075–2088. doi: 10.18632/oncotarget.28060

Figure 4. Freedom from progression categorized by arterial conduit favorability in 28 patients with intrahepatic cholangiocarcinoma treated with ablative radioembolization.

Figure 4